GlassScriptPhysician profile
Scott A Boruchow
NPI 1174772354
$2,703.73
in general payments reported to CMS, 2019-2025
32 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $61.71 · 2021: $798 · 2022: $718 · 2023: $130 · 2024: $504 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $287.33 | 2019-2025 | Proclaim |
| Medtronic, INC. | $281.17 | 2022 | |
| Amgen INC. | $197.16 | 2019-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $194.32 | 2019-2025 | |
| Argenx US, INC. | $176.76 | 2022-2024 | Vyvgart Hytrulo |
| Abbvie INC. | $171.19 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $160.76 | 2021 | |
| Lilly USA, LLC | $149.98 | 2021-2024 | Kisunla |
| Eisai INC. | $140.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $115.36 | 2024 | Wainua |
| Genzyme Corporation | $113.08 | 2021-2025 | |
| Biogen, INC. | $94.98 | 2021-2023 | Tysabri, Vumerity |
| Emd Serono, INC. | $74.33 | 2021-2022 | |
| Celgene Corporation | $68.35 | 2022 | |
| Ucb, INC. | $53.63 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $51.01 | 2019-2023 | Ocrevus |
| Alnylam Pharmaceuticals INC. | $46.27 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $41.85 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.08 | 2022 | |
| Arbor Pharmaceuticals, INC. | $35.50 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $22.88 | 2023 | Soliris |
| Upsher-Smith Laboratories LLC | $21.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.70 | 2022 | |
| Allergan, INC. | $19.32 | 2022 | |
| Neurelis, INC. | $19.31 | 2021 | |
| Ge Healthcare | $17.90 | 2021 | |
| Neurocrine Biosciences, INC. | $16.83 | 2022 | |
| C2n Diagnostics, LLC | $16.78 | 2025 | Precivityad2 |
| Acadia Pharmaceuticals INC | $16.47 | 2022 | |
| Tg Therapeutics, INC. | $14.87 | 2025 | |
| Tanabe Pharma America, INC. | $14.52 | 2019 | |
| Biodelivery Sciences International, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Boruchow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.